Pfizer, Moderna, Johnson & Johnson – with more COVID vaccines available, does it matter which one you get? An expert on COVID variants discusses the available vaccines.

A meta-analysis finds that vision impairment and blindness are tied to an increased risk of mortality, prompting the need to address global eye health disparities.

A human genetics investigator discusses new RNA research developments that may aid in treating and preventing rare genetic diseases.

A new analysis finds higher baseline cognition scores for aging women, but a more rapid drop once cognitive decline begins.

University of Michigan research into COVID-19 complications, cancer and surprise medical bills competes among the nation’s top discoveries of the past year.

Pharmaceutical companies get special protection from the FDA for orphan drugs aimed at rare diseases, but a study shows high spending for common diseases for some such drugs.

For low-income pregnant patients, health insurance disruptions may make it less likely that they receive recommended prenatal and postpartum care.

Faculty, staff came together to grant one final wish for man with cystic fibrosis.

Hospital care for COVID-19 has been free to most patients but insurance companies may be ending that; a study of flu-related hospital bills suggests a coronavirus hospital stay could now cost $1,000 on average.

For Gina Yu, her initial exposure to the pandemic wasn’t from the bedside, but from within the media news storm.

Dentist appointments for kids have been harder to come by during the pandemic, with children Medicaid coverage facing greater barriers to care than those with private insurance.

Experts bring virtual care to a diverse range of patients in need.

Simplified scoring tool accurately measures inflammation and healing in the gut for children with Crohn’s disease, a type of inflammatory bowel disease.

A special Open Enrollment period for healthcare.gov insurance plans, and new price transparency rules for hospitals, mean good news for health insurance consumers.

A popular treatment for peripheral arterial disease is less effective and more expensive than other options. Experts explore several methods to bring the state toward higher-value vascular care.